About this trial
The purpose of the study is to investigate if Tisotumab Vedotin (HuMax®-TF-ADC) is safe and has an additive effect when used with other anti-cancer medications in the treatment of recurrent or advanced cervical cancer.
Where’s this trial being run?Cork University Hospital, University Hospital Waterford, and Mater Misericordiae University Hospital
Can I join this study / trial?
The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.
Why not Print this page and bring it with you. It will help your doctor and research team advise you.Print this page
For more detailed informationClick Here
ENGOT-cx8: A Phase 1b/2 Open-label Trial of Tisotumab Vedotin (HuMax®-TF-ADC) in combination with other agents in subjects with Recurrent or Stage IVB cervical cancer.
|Principal Investigator:||Dr Dearbhaile Collins (Cork University Hospital)|
Global: February 2019
Ireland: May 2019
|Global Recruitment Target:||140|
|Ireland Recruitment Target:||12|